US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Disc Medicine, Inc. - Common Stock
(NQ:
IRON
)
80.84
-2.00 (-2.41%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Disc Medicine, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers
↗
January 15, 2026
Via
Stocktwits
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
March 27, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
March 26, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
March 19, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
March 18, 2026
From
Schall Law
Via
GlobeNewswire
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
March 14, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection
↗
March 01, 2026
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce.
Via
The Motley Fool
Topics
Regulatory Compliance
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction
↗
February 25, 2026
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
Via
The Motley Fool
Topics
Regulatory Compliance
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
↗
February 25, 2026
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
↗
February 25, 2026
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
↗
February 25, 2026
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.
Via
The Motley Fool
Topics
Regulatory Compliance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
February 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
February 24, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
February 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns
↗
February 13, 2026
The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin.
Via
Stocktwits
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
February 13, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
February 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
January 27, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
January 12, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 12, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run
↗
January 11, 2026
This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’
↗
December 19, 2025
Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
Next >
